The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
Open accessAbstract
Purpose: We evaluated the pharmacokinetics (PKs), pharmacodynamics, safety, and efficacy of selinexor, an oral selective inhibitor of nuclear export compound, in patients with advanced soft tissue or bone sarcoma with progressive disease. Patients and Methods: Fifty-four patients were treated with oral selinexor twice per week (on days 1 and 3) at one of three doses (30 mg/m 2 , 50 mg/m 2 , or flat dose of 60 mg) either continuously or on a schedule of 3 weeks on, 1 week off. PK analysis was performed under fasting and fed states (low v high fat content) and using various formulations of selinexor (tablet, capsule, or suspension). Tumor biopsies before and during treatment were evaluated for pharmacodynamic changes. Results: The most commonly reported drug-related adverse events (grade 1 or 2) were nausea, vomiting, anorexia, and fatigue, which were well managed with supportive care. Commonly reported grade 3 or 4 toxicities were fatigue, thrombocytopenia, anemia, lymphopenia, and leukopenia. Selinexor was significantly better tolerated when administered as a flat dose on an intermittent schedule. PK analysis of selinexor revealed a clinically insignificant increase (approximately 15% to 20%) in drug exposure when taken with food. Immunohistochemical analysis of paired tumor biopsies revealed increased nuclear accumulation of tumor suppressor proteins, decreased cell proliferation, increased apoptosis, and stromal deposition. Of the 52 patients evaluable for response, none experienced an objective response by RECIST (version 1.1); however, 17 (33%) showed durable (≥ 4 months) stable disease, including seven (47%) of 15 evaluable patients with dedifferentiated liposarcoma. Conclusion: Selinexor was well tolerated at a 60-mg flat dose on a 3-weeks-on, 1-week-off schedule. There was no clinically meaningful impact of food on PKs. Preliminary evidence of anticancer activity in sarcoma was demonstrated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Cited by
Kalakonda, N., Maerevoet, M., Cavallo, F., Follows, G., Goy, A., Vermaat, J. S. P., Casasnovas, O., Hamad, N., Zijlstra, J. M., Bakhshi, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30120-4 · Cited by 339
Self-citationMutant NPM1 Maintains the Leukemic State through HOX Expression
Brunetti, L., Gundry, M. C., Sorcini, D., Guzman, A. G., Huang, Y.-H., Ramabadran, R., Gionfriddo, I., Mezzasoma, F., Milano, F., Nabet, B., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.005 · Cited by 313
Targeting Translation of mRNA as a Therapeutic Strategy in Cancer
Pal, I., Safari, M., Jovanovic, M., Bates, S. E., & Deng, C. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00530-y · Cited by 46
Metadata
- Authors
- Gounder, M. M., Zer, A., Tap, W. D., Salah, S., Dickson, M. A., Gupta, A. A., Keohan, M. L., Loong, H. H., D’Angelo, S. P., Baker, S., Condy, M., Nyquist-Schultz, K., Tanner, L., Erinjeri, J. P., Jasmine, F. H., Friedlander, S., Carlson, R., Unger, T. J., Saint-Martin, J.-R., Rashal, T., Ellis, J., Kauffman, M., Shacham, S., Schwartz, G. K., & Abdul Razak, A. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-09-10
- Volume
- 34
- Issue
- 26
- Pages
- 3166-3174
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2495597122
- Cited by
- 164
- References
- 1
- FWCI
- 15.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. https://app.cochat.ai/papers/10.1200/jco.2016.67.6346
- The paper
- Gounder, M. M., Zer, A., Tap, W. D., Salah, S., Dickson, M. A., Gupta, A. A., Keohan, M. L., Loong, H. H., D’Angelo, S. P., Baker, S., Condy, M., Nyquist-Schultz, K., Tanner, L., Erinjeri, J. P., Jasmine, F. H., Friedlander, S., Carlson, R., Unger, T. J., Saint-Martin, J.-R., . . . Abdul Razak, A. R. (2016). Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.67.6346
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.